—Mkt Cap: —P/E: —
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lig…
Industry Peers
Health Care Technologyloading…
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value276.66M USD
Revenue (TTM)204.17M USD
Gross Profit104.46M USD
Net Income (TTM)-66.54M USD
Revenue/Share1.597 USD
Last Price—
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees678
CountryUS
SectorHealth Care
IndustryHealth Care Technology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)20.84
PEG—
EV/EBITDA-7.62
EV/Revenue1.36
P/S2.50
P/B1.56
EPS (TTM)-0.58
EPS (Forward)0.19
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin51.84%
Oper. Margin-41.83%
EBITDA Margin-17.78%
Profit Margin-33.02%
ROE-19.47%
ROA-14.42%
Growth
Revenue Growth6.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.69M USD
CapEx (TTM)4.19M USD
FCF Margin3.14%
FCF Yield—
Net Debt-234.74M USD
Net Debt/EBITDA6.47
Balance Sheet
Debt/Equity0.07
Current Ratio4.69
Quick Ratio3.94
Book Value/Sh2.537 USD
Cash/Share2.031 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)5.688 USD
Target Range4.750 USD – 7.500 USD
# Analysts4
Ownership
Shares Out.129.14M
Float96.74M
Insiders8.43%
Institutions67.64%
Short Interest
Short Ratio13.8d
Short % Float7.60%
Short % Out.5.99%
Shares Short7.74M
Short (prev mo.)8.06M
Technical
SMA 504.376 USD
SMA 2004.479 USD
Beta1.23
S&P 52W Chg28.31%
Avg Vol (30d)—
Avg Vol (10d)1.36M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—